AtheroNova, Inc. (AHRO) Welcomes Fred Knoll To Board Of Directors

Nov. 08, 2012 8:26 AM ETAHRO
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Contributor Since 2008

QualityStocks ( assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future. QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. The content we provide via Seeking Alpha may be part of our efforts to widen a client’s exposure. To read our full disclaimer, visit

Biotech company AtheroNova today announced Fred Knoll, the principal and portfolio manager of Knoll Capital Management, as the newest member to the board of directors of AtheroNova.

Knoll has served in his current position at Knoll Capital since 1987, and was previously employed as an investment manager for General American Investors; was the U.S. representative on investments in leveraged buyouts and venture capital for Murray Johnstone Ltd. of Glasgow, UK; and was head of the New York investment group of UK-based Robert Fleming Inc., which was acquired by JP Morgan.

"As a leading investment manager, Fred brings a wealth of knowledge in emerging growth companies and will bring his expertise to our many opportunities as we transition into the next phase of clinical development at AtheroNova," Thomas W. Gardner, CEO of AtheroNova stated in the press release. "We welcome Fred to our board and look forward to working together as we develop AtheroNova's atherosclerosis regression and lipid modulation technology."

Knoll holds a Bachelor of Science in electrical engineering and computer science from Massachusetts Institute of Technology (MIT.), a Bachelor of Science in management from the Sloan School at MIT, and an MBA from Columbia University in finance.

AtheroNova operates through its wholly owned subsidiary, AtheroNova Operations, to focus on the discovery, research, development, and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits and to safely improve lipid profiles in humans. The company plans to develop multiple applications for its patents-pending therapies in market sectors that include: cardiovascular disease, stroke, peripheral artery disease, dementia and Alzheimer's, and erectile dysfunction, all of which have been linked to atherosclerosis.

For more information visit

Please see disclaimer on the QualityStocks website:

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.